CAR-T cell therapyThe world’s largest approved portfolio
- By mid-2026, China’s NMPA had approved nine CAR-T products, compared with seven in the United States and six in Europe.
- In June 2026, the NMPA approved satri-cel (satricabtagene autoleucel), the world’s first approved CAR-T therapy for a solid tumor, for advanced gastric cancer.
- CAR-T therapies are used for selected blood cancers. Response rates and durability vary by product, indication, and patient. Ruijin Hospital in Shanghai has participated in multicenter research on commercial CAR-T treatment in China.





















